Zhang Baodi, Wei Jia, Wu Xuan, Wang Lei, Huo Hongdan, Wang Junrong
Department of Surgery, First Branch of Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
Dialysis Room, First Branch of Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
Exp Ther Med. 2018 Feb;15(2):1660-1665. doi: 10.3892/etm.2017.5567. Epub 2017 Nov 27.
Transurethral plasma kinetic resection is an efficient and safe surgery for the treatment of benign prostatic hyperplasia. Solifenacin succinate (SOL) is safe and clinically efficient for patients who endure transurethral resection of the prostate (TURP) during the perioperative period. The objective of this study was to evaluate the clinical optimal dose of SOL for nursing patients after TURP during the perioperative period. Patients were recruited and randomized into three groups: SOL (3 mg), SOL (6 mg), and SOL (10 mg). All patients received medical care for 3 weeks after TURP. Levels of inflammatory cytokines, including IL-6, epithelial neutrophil activation peptide-7 (ENA-7), tumor necrosis factor (TNF)-α, interleukin (IL)-2, IL-17 and IL-8, were investigated in the patients of all three groups. The efficacy of SOL was analyzed via the following scores: International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OBSS), short-form voiding (SFV) and storage score (TS) of International Continence Society (ICS). Outcomes showed that IL-2 and ENA-7 plasma concentration levels were upregulated, whereas TNF-α, IL-6, IL-17 and IL-8 were downregulated, in all three groups. The findings showed that patients that received SOL (6 mg) exhibited significant improvements compared to the other patient groups from baseline to the end of treatment, as determined by IPSS, OBSS, ICS, SFV, TS (P<0.01). In conclusion, these results indicate that SOL (6 mg) is the optimal dose for patients who undergo TURP during the perioperative period. Notably, treatment with SOL (6 mg) exhibited significant additional benefits in terms of lower urinary tract symptoms during the early recovery period after TURP, suggesting SOL is clinically significant for nursing patients who suffer have undergone TURP during the perioperative period.
经尿道等离子体动力切除术是治疗良性前列腺增生的一种有效且安全的手术。琥珀酸索利那新（SOL）对于在围手术期接受经尿道前列腺切除术（TURP）的患者而言是安全且临床有效的。本研究的目的是评估围手术期TURP术后护理患者的SOL临床最佳剂量。招募患者并随机分为三组：SOL（3毫克）组、SOL（6毫克）组和SOL（10毫克）组。所有患者在TURP术后接受3周的医疗护理。对所有三组患者的炎症细胞因子水平进行了研究，包括白细胞介素（IL）-6、上皮中性粒细胞激活肽-7（ENA-7）、肿瘤坏死因子（TNF）-α、白细胞介素（IL）-2、IL-17和IL-8。通过以下评分分析SOL的疗效：国际前列腺症状评分（IPSS）、膀胱过度活动症症状评分（OBSS）、国际尿控协会（ICS）的简式排尿（SFV）和储尿评分（TS）。结果显示，所有三组中IL-2和ENA-7血浆浓度水平上调，而TNF-α、IL-6、IL-17和IL-8下调。研究结果表明，根据IPSS、OBSS、ICS、SFV、TS测定，接受SOL（6毫克）治疗的患者从基线到治疗结束与其他患者组相比有显著改善（P<0.01）。总之，这些结果表明SOL（6毫克）是围手术期接受TURP患者的最佳剂量。值得注意的是，SOL（6毫克）治疗在TURP术后早期恢复期间对下尿路症状有显著的额外益处，表明SOL对围手术期接受TURP的护理患者具有临床意义。
